Search

everythinglearnresearchcommunity

for

Search:↓

Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.

The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Active oxygen scavengers can reverse the suppression of hair cell growth caused by androgens.

Astragaloside A may help fight lung cancer by targeting specific proteins.

Androgen receptor inactivation delays skin cancer onset and reduces incidence in mice, with gender differences in susceptibility.

Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.

A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.

New compounds called benzoquinolinones may treat conditions linked to excess DHT.

The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Reduced alpha smooth muscle actin may cause hair loss in androgenetic alopecia.

Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.

AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.

New steroid derivatives show promise as anticancer agents, even against resistant cells.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Setipiprant may reduce inflammation by blocking an enzyme called aldose reductase.

The compound 4c showed strong potential as an anticancer agent.

SRD5A1 is crucial in advanced prostate cancer, and blocking both SRD5A1 and SRD5A2 is more effective than targeting SRD5A2 alone.

Higher TGF-β signaling may increase skin cancer risk in organ transplant recipients.

Antiandrogens help treat hormone-related conditions in both men and women.

Antizyme reduces tumor growth and normalizes skin cell development affected by MEK.

A new topical treatment for hair loss shows promise by targeting androgen receptors.

SMAD4 is crucial for muscle repair in young adults but not in aged mice.

The substance MK386 effectively blocked testosterone conversion and reduced cell growth in certain skin cells, but inhibiting 5α-reductase alone may not greatly improve acne.

Antiandrogens can treat acne, hirsutism, and seborrhea by reducing sebum production and androgen action.

AP-1 controls tumor cell type by affecting key signaling pathways.